Aggredyne, a biomedical diagnostics firm involved in platelet function testing, raised $3 million in a Series A convertible preferred stock funding round. The Houston firm is preparing to apply for U.S. marketing approval for its laser-light scattering platelet aggregometer, AggreGuideTM A-100, and related blood platelet tests.
Aggredyne pulls in $3M in latest financing round
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|